Abbott Launches First Fully Absorbing Stent In US Market
This article was originally published in The Gray Sheet
Abbott looks to Absorb GT1, the first fully bioresorbable coronary scaffold to gain FDA approval, to help accelerate growth. But it still has yet to be shown superior to conventional drug-eluting stents, and it also has metal stents with bioresorbable polymers to contend with.
You may also be interested in...
While a panel of FDA experts almost unanimously voted to recommend Abbott's fully bioabsorbable Absorb scaffold, analysts say the stent is unlikely to take significant market share, at least in its current form.
Competing visions of the future of percutaneous coronary interventions were on display at TCT year, with Boston Scientific pushing its Synergy bioabsorbable polymer-coated, drug-eluting metal stent platform as the better long-term option to fully-resorbable scaffolds of the type Abbott is first out of the gate with.
Boston Scientific wants to expand the lead against other stents used by interventional cardiologists with the launch of its Synergy drug-eluting stent that they expect will become the workhorse of the industry to handle a broad range of surgeries to treat coronary artery disease. "Our belief is that the target for Synergy is [the] entire market," says Boston Scientific's senior VP and president of its interventional cardiology unit.